---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116413"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:03:45.013919+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Replimune reports Q2 FY2025 net loss $53.1M; BLA for RP1 in melanoma on track before year-end

## Summary
- Completed pre-BLA meeting with FDA; BLA submission for RP1+nivolumab in anti-PD1 failed melanoma via accelerated approval path on track by end of 2024.
- IGNYTE primary analysis: 33.6% ORR at 12 months by modified RECIST 1.1; median DOR from response initiation 21.6 months.
- Cash, cash equivalents and short-term investments $432.1M as of Sep 30, 2024; funding operations into H2 2026.
- R&D expenses $43.4M, down from $49.1M; net loss $53.1M, improved from $60.0M YoY.
- RP2 in uveal melanoma: registration-directed trial with first patient enrollment expected Q1 2025.

## SEC filing metadata
- accession: 0001104659-24-116413
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465924116413/0001104659-24-116413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465924116413/tm2428095d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116413
- JSON: https://secwatch.observer/filing/0001104659-24-116413.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.